Cure My Disease

Don't miss your cure!

 Log in / Sign up

Anemia drug MIRCERA studied in kidney patients before dialysis

NCT ID NCT02567188

Completed Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looked at how well MIRCERA works for anemia in people with chronic kidney disease stages 3-4 who are not yet on dialysis. Researchers tracked 144 patients over 12 months to see if their hemoglobin levels stayed in a healthy range. The goal was to gather real-world data on safety and effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MIRCERA (a drug that stimulates red blood cell production)
What this could lead to
If successful, this study could confirm that MIRCERA helps manage anemia in pre-dialysis kidney disease patients, potentially improving energy and quality of life.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by other factors. It does not prove MIRCERA is better than other treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANEMIA

Contacts and locations

Locations

  • Study site

    Angeholm, S-262 81, Sweden

  • Study site

    Bollnäs, 821 81, Sweden

  • Study site

    Eskilstuna, 63188, Sweden

  • Study site

    Gävle, 80187, Sweden

  • Study site

    Gothenburg, 41345, Sweden

  • Study site

    Gothenburg, S-402 76, Sweden

  • Study site

    Huddinge, 14186, Sweden

  • Study site

    Jönköping, 55185, Sweden

  • Study site

    Karlshamn, S-374 80, Sweden

  • Study site

    Karlstad, 65185, Sweden

  • Study site

    Kristianstad, 29185, Sweden

  • Study site

    Linköping, S-581 85, Sweden

  • Study site

    Mölndal, S-431 80, Sweden

  • Study site

    Norrköping, 60182, Sweden

  • Study site

    Skövde, 54185, Sweden

  • Study site

    Stockholm, 17176, Sweden

  • Study site

    Stockholm, 18288, Sweden

  • Study site

    Umeå, 90185, Sweden

  • Study site

    Värnamo, 33185, Sweden

  • Study site

    Västervik, 59381, Sweden

More trials for these conditions

Other studies related to the condition(s) this trial covers.